FDA Permits New Sunscreen Ingredient After 20 Years - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Permits New Sunscreen Ingredient After 20 Years

The sunscreen ingredient, which has been marketed internationally for years, is considered generally recognized as safe and effective for use in adults and pediatric patients aged 6 months and older.

  • By

  • Kathryn Wighton

  • June 9, 2026

  • 2 min

Share

Objective:

To announce the addition of bemotrizinol to the OTC sunscreen monograph.

Key Findings:
  • Bemotrizinol provides protection against both UVA and UVB radiation, as stated by the FDA.
  • It has low systemic absorption following topical use, according to the FDA.
  • The ingredient has been marketed in Europe and other countries prior to U.S. authorization, as noted by the FDA.
Interpretation:

Limitations:
  • The FDA's action does not approve any specific sunscreen product containing bemotrizinol.
Conclusion:

Original Source(s)

FDA Permits New Sunscreen Ingredient After 20 Years

  • by Kathryn Wighton

  • June 9, 2026

Related Content

Use of digital health interventions by outdoor workplaces in Australia: A focus on skin cancer prevention interventions

Medical Oddities: A fowl cause of urinary obstruction

A rogue chicken bone, stalled sweat, yoga for IBS, and L-theanine for sleep is break room fodder this week.

Connected Health May Match In-Person AD Care

A randomized clinical trial found that a team-based connected health model achieved equivalent improvements in atopic dermatitis severity and symptoms compared with conventional in-person care over 12 months.